{"id":"cnto-136","safety":{"commonSideEffects":[{"rate":null,"effect":"Infections"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:15:18.734622","_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By binding to IL-12 and IL-23, CNTO 136 inhibits the signaling pathways that lead to the production of pro-inflammatory cytokines, thereby reducing inflammation and potentially alleviating symptoms in autoimmune diseases.","oneSentence":"CNTO 136 is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:31:30.396Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT04380961","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-04-24","conditions":"Critical Confirmed Coronavirus Disease (COVID)-19","enrollment":212},{"nctId":"NCT01856309","phase":"PHASE3","title":"Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-08-07","conditions":"Arthritis, Rheumatoid","enrollment":1820},{"nctId":"NCT01606761","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08-06","conditions":"Arthritis, Rheumatoid","enrollment":878},{"nctId":"NCT00718718","phase":"PHASE2","title":"A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2008-08-11","conditions":"Arthritis, Rheumatoid","enrollment":187},{"nctId":"NCT01604343","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-08-15","conditions":"Arthritis, Rheumatoid","enrollment":1670},{"nctId":"NCT02019472","phase":"PHASE3","title":"A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-04-04","conditions":"Arthritis, Rheumatoid","enrollment":559},{"nctId":"NCT01636557","phase":"PHASE1","title":"A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2012-10-11","conditions":"Arthritis, Rheumatoid","enrollment":12},{"nctId":"NCT01689532","phase":"PHASE3","title":"A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2012-11","conditions":"Arthritis, Rheumatoid","enrollment":122},{"nctId":"NCT01273389","phase":"PHASE2","title":"An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2011-08","conditions":"Lupus Nephritis","enrollment":25},{"nctId":"NCT01702740","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Centocor Research & Development, Inc.","startDate":"2007-03","conditions":"Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic","enrollment":49},{"nctId":"NCT00844909","phase":"PHASE1","title":"A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers","status":"COMPLETED","sponsor":"Centocor, Inc.","startDate":"2009-01","conditions":"Healthy","enrollment":62}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CNTO 136","genericName":"CNTO 136","companyName":"Centocor, Inc.","companyId":"centocor-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CNTO 136 is a monoclonal antibody that targets interleukin-12 (IL-12) and interleukin-23 (IL-23), which are involved in inflammatory responses. Used for Moderate to severe plaque psoriasis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}